A one-year randomized, prospective, parallel, open comparison of subjective well-being in schizophrenic out-patients treated with quetiapine XR (Seroquel XR) or oral risperidone at flexible dose in a naturalistic setting.

Trial Profile

A one-year randomized, prospective, parallel, open comparison of subjective well-being in schizophrenic out-patients treated with quetiapine XR (Seroquel XR) or oral risperidone at flexible dose in a naturalistic setting.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Quetiapine (Primary) ; Risperidone
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms RECOVER
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Oct 2012 Last checked against European Clinical Trials Database record.
    • 28 Apr 2012 Trial locations identified as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top